Role of Anti-HER-2 Therapies in the Neo-Adjuvant Setting: Is Complete Pathological Response a Solid Surrogate?

E-ISSN： 1876-1038|10|2|82-89

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.10, Iss.2, 2015-01, pp. : 82-89

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial

Reviews on Recent Clinical Trials, Vol. 12, Iss. 3, 2017-11 ,pp. : 216-222

Bentham Science Publishers

Access to resources Recommend Favorite

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies

CANCER, Vol. 122, Iss. 17, 2016-09 ,pp. : 2654-2662

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy

Oncology, Vol. 81, Iss. 1, 2011-09 ,pp. : 30-38

Karger

Access to resources Recommend Favorite

Association d’anticorps anti-EGFR et anti-HER2

By Larbouret Christel Robert Bruno Teulon Isabelle Azria David Pèlegrin André

Médecine/sciences, Vol. 23, Iss. 10, 2010-12 ,pp. : 800-803

Edp Sciences

Access to resources Recommend Favorite

Anti-HER2 Therapy in Elderly Breast Cancer Patients

Reviews on Recent Clinical Trials, Vol. 9, Iss. 4, 2014-01 ,pp. : 263-266

Bentham Science Publishers

Access to resources Recommend Favorite